Description: Applied Therapeutics, Inc., a biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-001 that is in phase II clinical trials for treating diabetic cardiomyopathy, as well as is in phase I clinical trials to treat diabetic peripheral neuropathy. The company’s preclinical stage products include AT-001 for acute myocardial infraction; AT-007 for treating galactosemia; AT-003 to treat diabetic retinopathy; and AT-104 for the treatment of orphan hematological oncology. Applied Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
Home Page: www.appliedtherapeutics.com
APLT Technical Analysis
545 Fifth Avenue
New York,
NY
10017
United States
Phone:
212 220 9226
Officers
| Name | Title |
|---|---|
| Dr. Shoshana Shendelman Ph.D. | Chair of the Board of Directors, Founder, Pres, CEO & Sec. |
| Dr. Riccardo Perfetti M.D., Ph.D. | Chief Medical Officer |
| Mr. Chids Mahadevan | Sr. VP of Fin. & Interim Principal Financial Officer |
| Mr. Steven Ortega | Chief Accounting Officer |
| Mr. Adam Hansard | Chief Commercial Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.2194 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2019-05-14 |
| Fiscal Year End: | December |
| Full Time Employees: | 26 |